Clinical Outcomes of Immune Checkpoint Inhibitor Diabetes Mellitus at a Comprehensive Cancer Center
Rebecca Jeun, Priyanka Iyer, Conor Best, Victor Lavis, Jeena Varghese, Sireesha Yedururi, Veronica Brady, Isabella C. Glitza Oliva, Ramona Dadu, Denái R. Milton, Kristy K. Brock, Sonali Thosani
Abstract
Introduction: Immune checkpoint inhibitor-associated diabetes mellitus (ICI-DM) is a rare adverse event. In this study, we characterize clinical outcomes of patients with ICI-DM and evaluate survival impact of this complication on melanoma patients. Research design & methods: We conducted a retrospective review of 76 patients diagnosed with ICI-DM from April 2014 to December 2020. Results: 68% of patients presented in diabetic ketoacidosis, 16% had readmissions for hyperglycemia, and hypoglycemia occurred in 70% of patients after diagnosis. Development of ICI-DM did not impact overall survival or progression-free survival in melanoma patients. Conclusion: Development of ICI-DM is associated with long-term insulin dependence and pancreatic atrophy; the use of diabetes technology in this patient population can help improve glycemic control.